SCHEMBL2437251

SCHEMBL2437251

Cc1nc2ccccc2nc1-c1cc2nc(Cl)cc(Cl)n2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 7/20 0.41
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NFKB1 P19838 1/20 0.39
HTT P42858 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
DPP4 P27487 5/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
DPP8 Q6V1X1 4/20 0.38
DPP9 Q86TI2 3/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2443008 0.88 KDM4E (0.38) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL2439004 0.88 KDM4E (0.38) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL2439159 0.88 NPC1 (0.37) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL2409936 0.86 DPP4 (0.36) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL2438425 0.86 PDE10A (0.45) PDE10ANPC1RAB9AALDH1A1KDM4E
SCHEMBL2440809 0.86 DPP4 (0.36) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL2443293 0.85 PDE10A (0.46) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL6898005 0.84 NPC1 (0.40) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL2437615 0.84 PDE10A (0.46) PDE10ANPC1RAB9AALDH1A1HPGD
SCHEMBL2438684 0.83 KDM4E (0.42) PDE10AKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A PDE10A 5/4885NPC1 4264/4885RAB9A 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.